This Week: Bizarre news from across the psychedelics space Happy April 1st! A self-styled ‘psychedelic biotech’ has doubled its R&D spend this Quarter, announcing a partnership with JSTOR. Upon further investigation, it appears the company has subscribed to JSTOR’s $19.50/month plan, and purchased four conical flasks. Speaking exclusively to Psilocybin Alpha, the company’s Chief Marketing Officer…


Previous articleCanada’s SAP Expansion Signals a Step Forward for Psychedelics
Next articleHealth Canada Approves First Special Access Program Requests for Psilocybin